allodynia from glp-1 Allodynia: Causes, Management, and the Link to Medications Benefit-Risk Assessment of GLP-1 Receptor

This will further expand its use in research settings and potentially its clinical applications

L- , ,

The decision should involve individualized risk-benefit assessment considering the specific autoimmune diagnosis, disease activity, and concurrent medications, with coordination between the prescribing clinician and the specialist managing the autoimmune condition

Recent studies have shown that Glycyl-l-histidyl-l-lysine (GHK) is a kind of natural human tripeptide which could inhibit inflammation and against neurodegenerative diseases, but neither its role nor the mechanisms in ICH have yet been explicit